We excluded trials for cancer specific mutations in PIK3CA, PIK3CB, AKT, or PTEN and trials for inhibitors of PI3K-α and -β (alpelisib, taselisib, serabelisib, HS-10352, GSK2636771), AKT (ipatasertib, AZD5363), mTOR (everolimus, TAK-228), or dual PI3K/mTOR (gedatolisib, samotolisib, HEC68498, paxalisib). This evidence concerns the gene AKT1 and cancer.